Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 1/20 | 0.47 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.40 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.39 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | NPY1R | P25929 | 5/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.37 |
| ▸ | CASP3 | P42574 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6506620 | 0.81 | KDM4E (0.52) | CTNNB1KDM4EALDH1A1KMT2APIN1 | |
| SCHEMBL6829039 | 0.79 | KDM4E (0.53) | CTNNB1KDM4EALDH1A1KMT2APIN1 | |
| SCHEMBL6139477 | 0.77 | P2RX3 (0.48) | P2RX3 | |
| SCHEMBL7342724 | 0.73 | L3MBTL1 (0.43) | KDM4EALDH1A1KMT2APPARG | |
| Hydrochloric Acid SCHEMBL8596989 | 0.70 | MEN1 (0.42) | CTNNB1KMT2ASMN1; SMN2P2RX3 | |
| SCHEMBL14616345 | 0.69 | ALDH1A1 (0.58) | KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL11681610 | 0.68 | KDM4E (0.62) | KDM4EALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL11604659 | 0.68 | ALDH1A1 (0.71) | CTNNB1KDM4EALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL31367787 | 0.68 | FABP4 (0.64) | CTNNB1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL1004258 | 0.68 | FABP4 (0.64) | CTNNB1KDM4EALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050032779-A1 | Benzimidazole derivatives, preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2005-02-10 | — | — | US | disclosed |
| US-6794382-B2 | 6-OXO-5,6-DIHYDRO-4H-IMIDAZO(4,5,1-IJ)QUINOLINE DERIVATIVES AS INHIBITORS OF ADP-RIBOSYLTRANSFERASE; CARDIOVASCULAR, IMMUNOLOGICAL, RESPIRATORY SYSTEM, AND NEURODEGENERATIVE DISORDER TREATMENT | SANOFI-SYNTHELABO (FR) | 2004-09-21 | — | — | US | disclosed |
| US-20030203893-A1 | Benzimidazole derivatives, preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2003-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032779-A1 | Benzimidazole derivatives, preparation and therapeutic use thereof | CBR3, CYP3A7, HDAC7 | CTNNB1 3036/4885TLR8 696/4885PKN1 1907/4885 |
| US-20030203893-A1 | Benzimidazole derivatives, preparation and therapeutic use thereof | CBR3, HRH4, CBR1 | CTNNB1 3416/4885TLR8 764/4885PKN1 2526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.